FMRP loss of function causes Fragile X syndrome (FXS) and autistic features. FMRP is a polyribosome-associated neuronal RNA-binding protein, suggesting that it plays a key role in regulating neuronal translation, but there has been little consensus regarding either its RNA targets or mechanism of action. Here, we use high-throughput sequencing of RNAs isolated by crosslinking immunoprecipitation (HITS-CLIP) to identify FMRP interactions with mouse brain polyribosomal mRNAs. FMRP interacts with the coding region of transcripts encoding pre-and postsynaptic proteins and transcripts implicated in autism spectrum disorders (ASD). We developed a brain polyribosome-programmed translation system, revealing that FMRP reversibly stalls ribosomes specifically on its target mRNAs. Our results suggest that loss of a translational brake on the synthesis of a subset of synaptic proteins contributes to FXS. In addition, they provide insight into the molecular basis of the cognitive and allied defects in FXS and ASD and suggest multiple targets for clinical intervention.
INTRODUCTION
Fragile X syndrome (FXS) was the first genetic disorder to link RNA regulation to human cognitive function. Loss of function of the Fragile X mental retardation protein (FMRP) causes FXS (Verkerk et al., 1991) , the most common inherited form of intellectual disability, which is further characterized by autistic behaviors, childhood seizures, and abnormal dendritic spines (Hagerman and Hagerman, 2002; Hernandez et al., 2009) . FMRP is an RNA binding protein (RNABP) whose function is incompletely understood, but is believed to be involved in translational regulation (Bassell and Warren, 2008; Gatto and Broadie, 2009; Costa-Mattioli et al., 2009; Zukin et al., 2009) . This is of particular interest because new protein synthesis is required for long-term synaptic plasticity (Kelleher et al., 2004; Klann and Dever, 2004; Richter and Klann, 2009; Sutton and Schuman, 2006) , a phenomenon thought to underlie the formation and persistence of memory (Malenka and Bear, 2004) . Some activity-regulated translational control pathways have been identified, such as the ERK and mTOR pathways regulating initiation , or eEF2 phosphorylation controlling elongation (Sutton et al., 2007) , but in general these are thought to have broad effects on translation. A specific set of transcripts and the proteins regulating them to mediate synaptic plasticity remain to be defined.
In the brain, FMRP is present in the neuronal cell body, proximal dendrites, and axons (Christie et al., 2009 ) and the majority of FMRP is associated with polyribosomes (Feng et al., 1997b; Khandjian et al., 2004; Stefani et al., 2004) . Moreover, a missense mutation in the second RNA binding domain (I304N) abolishes FMRP polyribosome association (Zang et al., 2009; Feng et al., 1997a) and causes a Fragile X phenotype in mice (Zang et al., 2009 ) and humans (DeBoulle et al., 1993) . Studies of Fmr1 knockout (KO) and I304N mice have documented a number of defects in synaptic plasticity (Pfeiffer and Huber, 2009; Zang et al., 2009 ). These observations suggest that FMRP regulates the translation of proteins important for proper synaptic function, yet there is no consensus as to how it might do so. In vitro, exogenous FMRP appears to bind and repress translation of a variety of transcripts including reporter mRNA (Laggerbauer et al., 2001; Li et al., 2001) . In dividing fibroblast cells, it has been suggested that transgenic Flag-tagged FMRP represses translation during elongation, but extrapolating this finding to endogenous FMRP in neurons is difficult (Ceman et al., 2003) . Underscoring the uncertainty of such a connection, Napoli et al. (2008) found that nonpolyribosomal FMRP in synaptoneurosomes can repress translation by inhibiting cap-dependent initiation through interaction with the eIF4E-BP, CYFIP1. However, this is likely to account for only a small fraction of FMRP function in vivo as the vast majority of the protein is polyribosome-associated.
A key to understanding FMRP function is to identify its RNA targets. Efforts have been made to identify specific FMRP target mRNAs by coimmunoprecipitation (IP) and microarray analysis , antibody positioned RNA amplification (APRA) (Miyashiro et al., 2003) , and bioinformatic approaches Darnell et al., 2001 ). However, these approaches do not identify RNA binding sites within transcripts, have inherent signal to noise issues (Mili and Steitz, 2004; Darnell et al., 2005b; Licatalosi and Darnell, 2010) , and are hampered by difficulties in bioinformatic prediction of complex RNA folding (Darnell et al., , 2005a . The net result is that they have met with limited success either in deriving a consensus set of FMRP mRNA targets, in identifying mRNAs that can be validated as targets in genetic systems, or in defining FMRP function.
We recently developed a general means of identifying RNAprotein interaction sites in vivo termed crosslinking-IP (CLIP) (Licatalosi and Darnell, 2010; Darnell, 2010) . CLIP uses ultraviolet irradiation to penetrate tissue and create a covalent bond between proteins and RNA molecules that are in direct contact (within a bond-length). CLIP, particularly when combined with high-throughput sequencing (HITS-CLIP), has been able to identify functional RNA-protein interaction sites in various contexts.
Here we have applied HITS-CLIP to the mouse brain in order to identify FMRP-mRNA interactions. We have used the resulting set of robust FMRP targets to drive in vitro and in vivo functional assays that define the molecular role of FMRP in controlling translation.
RESULTS

FMRP RNA Targets in Mouse Brain Polyribosomes
To develop FMRP CLIP ( Figure 1A ), we took advantage of the observation that 85%-90% of FMRP is associated with polyribosomes in the brain ( Figures 1B-1D ) as a purification step (Stefani et al., 2004) . This eliminated detectable background RNA from IPed FMRP-RNA crosslinked complexes ( Figure 1E ). After RT-PCR amplification of crosslinked RNAs, products were readily detected from wild-type (WT) but not Fmr1 KO brain (Figure 1F) . Using this protocol, we performed five biologic replicates using two independent antibodies to FMRP. To assess the specificity and reproducibility of FMRP RNA binding we repeated CLIP in biologic replicate using a second protocol ( Figure 1A ) crosslinking intact brain slices, increasing the stringency of denaturation, and purifying Hu:RNA complexes (Darnell et al., 2009 ) from the same lysate as a control for specificity ( Figures 1G-1I) .
We analyzed FMRP-crosslinked RNA tags from these seven independent experiments. Overall, 22 million tags were unambiguously mapped to the mouse genome, and after elimination of PCR duplicates, 163,904 unique sequences were analyzed (Table S1 available online). The results were very reproducible, with high correlations seen between exonic tag number per gene in CLIP experiments using different anti-FMRP antibodies, purification protocols and sequencing platforms (Figures S1A and S1B). The results were specific, as little correlation was seen between FMRP mRNA targets and either Hu targets or those of another neuronal RNABP, Nova (Figures S1C and S1D) . Importantly, the number of FMRP tags per transcript showed little correlation with transcript abundance or length (Figures S1E and S1F) . Taken together, these data demonstrate that FMRP reproducibly crosslinks to a subset of brain mRNAs in a manner distinct from other neuronal RNABPs.
Identity and Functions Encoded by FMRP Target Transcripts
We next defined the set of FMRP-mRNA interactions. We identified transcripts to which FMRP reproducibly crosslinked across the seven independent experiments, and used the number of unique tags per transcript in each experiment to rank the targets, allowing us to determine a chi-square score and false discovery rate (FDR) for each target based on rank and reproducibility. We identified a stringent set of 842 FMRP target transcripts (FDR < 0.01) (Tables S2A-S2C ). These FMRP targets were detectable with both antibodies (100%), using both CLIP protocols (100%), different sequencing platforms (100%), and were biologically reproducible (99% were detectable in at least six of seven experiments). It is likely that this analysis underestimates the true number of FMRP-regulated mRNAs; in addition to the conservative FDR threshold, some targets are likely to be rare, present in only a fraction of cells, or to interact with FMRP only under specific conditions. Therefore the absence of crosslinking to any one mRNA should be interpreted with caution.
Comparison of FMRP mRNA targets with a target list previously generated using FMRP-RNA co-IP (RIP-CHIP) from mouse brain ) found significant overlap. Fifty-four percent of RIP-CHIP targets (p = 2.4 3 10 À121 ; Table S2C and   Table S3A ) were present in the FMRP CLIP target list, accounting for 24% of CLIP targets. However, despite the fact that our conditions were much more stringent than those used in RIP-CHIP, our data conservatively identified 661 novel FMRP mRNA targets not found previously. We used the DAVID Bioinformatics database to analyze the gene ontology (GO) terms assigned to them. The 842 FMRP targets were compared with the total mRNA population present within the polyribosomal fractions from which FMRP:RNA complexes were captured, and independently with a database of the transcriptome of neurons purified from mouse brain at similar ages (Cahoy et al., 2008) (Figure 2A and Table S3B ). In both analyses, proteins encoded by FMRP-bound transcripts were enriched in those related to neuronal and synaptic transmission and regulation of small GTPase mediated signaling. FMRP was crosslinked to multiple members of many gene families (Table S2B) .
We also compared FMRP target mRNAs to the curated data set of mouse brain synaptic proteins (Croning et al., 2009 ). This identified an especially strong overlap with the postsynaptic proteome (32% of FMRP targets, p = 2.1 3 10
À83
; Figure 2B and Tables S3A and S3C ). Strikingly, a significant fraction of the mGluR5 (62%, p = 5.8 3 10 À22 ; Tables S3A and S3D) revealed that FMRP also binds mRNAs encoding approximately one-third of the proteins in the presynaptic proteome (p = 6.4 3 10 À33 ; Figure 2B and Tables S3A and S3F ). We used Ingenuity software to identify the top pathways enriched in FMRP targets ( Figure S2A and Table S4 ). The most significant overlaps included synaptic signaling pathways: synaptic longterm potentiation, glutamate receptor signaling, neuropathic pain signaling, GABA receptor signaling, synaptic LTD, and CREB signaling in neurons. Intracellular signaling pathways enriched in FMRP targets (p < 0.05) included calcium, PKA, PLC, G protein coupled receptor, RhoA, cAMP, and PI3K/Akt signaling pathways. This suggests a direct role for FMRP in regulating translation of the pre-and postsynaptic proteome and synaptic plasticity, likely underlying cognitive and behavioral changes in patients with FXS, as well as epilepsy and altered pain sensitivity (Price et al., 2007; Symons et al., 2003) .
Overlap of FXS and Autism Spectrum Disorders
FXS is the leading monogenic cause of autism spectrum disorders (ASDs), accounting for up to 5% of all cases (Kelleher and Bear, 2008) , and 90% of affected males show autistic behaviors (Hernandez et al., 2009 (Table S5 ). The ability of FMRP to repress translation of target mRNAs (see below) suggests that FXS, and by extension, some cases of ASD, may result from the overexpression of specific dosage-sensitive genes through loss of translational suppression. Gene overexpression can occur due to copy number variations (CNVs) caused by de novo segmental duplications, and several CNV association studies have established links to ASD (Pinto et al., 2010; Sebat et al., 2007) . We found a significant number (25/196) of candidate autism susceptibility genes in duplicated loci are FMRP targets (Table S3A and Table S5 ; p = 0.001). CNVs due to deletions showed less overlap and did not reach significance (12/121, p = 0.28). Taken together, the overlap between FMRP target transcripts and genes linked to the ASDs, particularly overexpressed genes, provides a new connection between loss of function of FMRP and the development of autistic symptoms in patients.
FMRP Binds Coding Sequences and Stalls Ribosomes
Sixty-six percent of FMRP mRNA binding was within the coding sequence (CDS), with no specific position relative to the start and stop codons, and with lower tag density in the 3 0 or 5 0 UTRs. In comparison, RNA tags of the neuronal Hu proteins mapped predominantly to the 3 0 UTR of target transcripts ( Figure 2C ).
This distribution of FMRP binding could arise in a population analysis from the sum of binding at unique positions in different transcripts. To exclude this possibility, we examined FMRP binding to individual targets, which also showed an even distribution of tags along the CDS ( Figure 2D and Figures S2B-S2G), whereas in contrast, Hu binding to its top-ranked targets was restricted to very specific binding sites in 3 0 UTRs ( Figure 2E ).
The distribution of FMRP binding was unexpected. FMRP crosslinking to the CDS is not easily reconciled with findings that most FMRP appears to be associated with actively translating polyribosomes and that this association is sensitive to EDTA and RNase (Stefani et al., 2004) , sodium azide that blocks initiation (Ceman et al., 2003; Feng et al., 1997a) , and puromycin (Stefani et al., 2004) , an aminoacyl-tRNA analog that causes translocating ribosomes to be released. Treating N2a cells with puromycin or hippuristanol, an inhibitor of translation initiation, suggested that, after ribosomal ''run-off,'' FMRP was associated with mRNAs still loaded with several ribosomes, in contrast to ribosomal protein P0 (rpP0) or poly(A) binding protein (PABP) ( Figure S3A ). Thus FMRP appears to associate with the CDS of transcripts on which some of the ribosomes may be stalled.
Loss of FMRP Function Relieves Ribosome Stalling
To assess the role of endogenous FMRP on translation of individual neuronal mRNAs, we developed an in vitro translation system programmed with endogenous brain polyribosomes (the ''IVT EBP system'') to maintain normal RNA-protein stoichiometry ( Figure 3A ). In the presence of puromycin at 30 C, ribosomal run-off was evident within 2 min, plateaued by 15 min, and was saturable, as neither a 10-fold increase in puromycin nor incubation for up to 45 min caused additional run-off (Figure S3) . No loss of polyribosome integrity was observed in parallel reactions incubated with cycloheximide (CHX) at 30 C for up to 45 min, ruling out nuclease activity. Ribosomal run-off could be detected in the presence of hippuristanol, reflecting natural ribosome release at the stop codon ( Figure 3B ). This run-off was accompanied by 35 S-methionine incorporation in a time-and brain polyribosome-dependent manner that was not increased if hippuristanol was omitted (Figures S3B and S3C) , indicating that elongation can occur on pre-existing brain polyribosome-associated mRNAs in the absence of initiation in the IVT EBP system.
After ribosomal run-off in the presence of puromycin, FMRP shifted in a time-dependent manner to fractions containing approximately five to eight ribosomes, recapitulating the behavior of FMRP in cells ( Figure 3C and Figure S3A ). In contrast, PABP or Hu shifted to lighter fractions, as did FMRP when EDTA was added to dissociate ribosomes ( Figure 3C ). In addition, natural run-off occurring in the presence of hippuristanol also resulted in retention of FMRP in large complexes in the IVT EBP the CDS (gold). In contrast, Hu tags were predominantly present within the 3 0 UTR (red) or mapped within 10,000 nt downstream of annotated genes (pink, downstream 10K), a region rich in unannotated 3 0 UTR sequences. system ( Figure 3B ). Based on the results of multiple experiments, the total amount of FMRP present on polyribosomes was not significantly changed before and after run-off. If FMRP regulates the translation of its mRNA targets one might anticipate that the number of ribosomes associated with these target transcripts would be altered in its absence. We estimated the steady-state number of ribosomes associated with nine FMRP target mRNAs or nine nontarget mRNAs by analyzing transcript distribution on polyribosome gradients. We found no reproducible differences in the sedimentation profile of any of these mRNAs in the presence or absence of functional FMRP in two different mouse FXS models (Figure 4 , first column, and Figure S4A ). Moreover, global analysis of total and polyribosome-associated mRNA levels identified no statistically significant changes between six pairs of Fmr1 KO and WT littermates (other than the Fmr1 transcript itself; described in Extended Experimental Procedures; Gene Expression Omnibus [GEO] database accession number GSE26809). These results were unexpected, given prior reports of FMRPdependent changes in mRNA polyribosome distribution. Although we cannot rule out that differences such as the cell types (e.g., human lymphoblastoid cell lines) or subcellular fractions (e.g., synaptoneurosomes) (Zalfa et al., 2003; Muddashetty et al., 2007) used in these studies may account for this discrepancy, our results clearly demonstrate that on a cell population level there is no FMRP-dependent difference in steady state mRNA polysome distribution in the P8-P25 mouse brain.
The steady state number of ribosomes on a transcript is not a measure of active translation. There are numerous instances in which significant inhibition of protein synthesis is not accompanied by a decrease in the number of ribosomes associated with the encoding mRNAs (Olsen and Ambros, 1999; Clark et al., 2000; Braat et al., 2004; Nottrott et al., 2006; Maroney et al., 2006; Petersen et al., 2006; Lytle et al., 2007) . Therefore, we separated translocating from stalled ribosomes by puromycin run-off in the IVT EBP system and assessed the number of puromycin-insensitive ribosomes remaining on target and nontarget transcripts. In the presence of FMRP, target transcripts were associated with more residual ribosomes after run-off than in the absence of functional FMRP (WT versus Fmr1 KO or I304N brain; Figure 4A , columns 2 and 3). Importantly, such differences were specific to FMRP-target transcripts ( Figure 4B ), suggesting that ribosomes are stalled on FMRPbound mRNAs in an FMRP-dependent manner in vivo, with stalling relieved in mice harboring either of two different FMRP loss-of-function mutations.
All three FMRP paralogs (''FXRP'' proteins FMRP, FXR1P, and FXR2P) show significant functional redundancy in binding to RNA and polyribosomes (Darnell et al., 2009) , including the ability to be fully displaced from polyribosomes by a high affinity in vitro selected RNA ligand (kissing complex RNA [kcRNA]; Figure S4B) (Darnell et al., 2005a) . We compared the mRNA distribution of FMRP target and nontarget mRNAs when WT brain polyribosomes were acutely incubated with kcRNA during Figure S4A ). Prior to run-off (first column; CHX treated [''steady-state''] polyribosomes; second column, yellow line), no changes in mRNA distribution were evident between WT (black triangles), Fmr1 KO (red squares), or I304N knock-in (orange diamonds) brain polyribosomes. The same mRNAs were then analyzed in the IVT EBP system in puromycin to achieve run-off separating translocating from stalled ribosomes in three distinct FMRP loss-of-function systems (Fmr1 KO [second column, red circles versus WT in black], I304N [third column, orange diamonds versus WT in black], and from WT polyribosomes treated with kcRNA decoy to acutely disrupt FMRP polyribosome association [fourth column, red circles] compared with a nonfunctional kcRNA point mutant [kcRNA C50G , black]). Data are plotted as a fraction of total mRNA on the gradient; error bars represent SD from three technical replicates. See also Figure S4 . puromycin run-off. Removal of FXRPs with kcRNA but not a nonbinding point mutant (kcRNA C50G ) also resulted in apparent relief of ribosome stalling specifically on FMRP target transcripts (Figure 4, column 4) . Significantly, addition of kcRNA after run-off did not cause a shift in the distribution of mRNAs, ruling out the possibility that observed changes in mRNA distributions were due to the loss of the mass of FXRPs alone ( Figure S4C ). To confirm that FXRPs stall ribosomes in vivo, we repeated the puromycin run-off assay in N2A cells, comparing untreated cells with loss of function by knockdown of FXR1P, FXR2P, and FMRP ( Figures S4D and S4E) . The FXRP-dependent association of target mRNAs with puromycin-insensitive ribosomes was remarkably similar to that seen in the brain polyribosomeprogrammed translation assay, underscoring the relevance of the in vitro system to living cells. Finally, addition of EDTA to remove all ribosomes caused some mRNAs to migrate to lighter fractions, consistent with the presence of residual ribosomes on some transcripts (those with more ribosomes initially, unrelated to whether the transcripts were FMRP targets; Figure S5 ). Taken together, these results demonstrate that acute loss of polyribosome-associated FMRP yields the same relief of translational repression as long-term loss of function in mouse models, indicating that ribosome stalling is likely to be caused directly and reversibly by FMRP.
We weighted the mRNA distribution on these plots according to the estimated number of ribosomes in each fraction (an FMRP-dependent ribosome retention score [RRS], a measure of the difference between the number of ribosomes remaining on transcripts after run-off in the presence versus absence of FMRP; Figure 5 and Figure 6A ). This analysis demonstrated a statistically significant difference between the nine FMRP target and nine nontarget mRNAs in all three loss-of-function models ( Figure 6B ). To generalize these findings, we assessed the distribution of 39 transcripts (20 FMRP targets and a set of comparable nontargets, controlled for length, abundance, and neuronal expression) after run-off in the IVT EBP assay using the kcRNA decoy (Table S6 ). All 39 transcripts were analyzed with no prior assumptions, and with no exclusion of outliers. The overall RRS scores correlated well with FMRP target binding assessed by CLIP (c 2 score, R 2 = 0.53, or by tags per gene, R 2 = 0.49), and were significantly different between targets and nontargets ( Figures 6C and 6D ). There was a small effect on some nontarget transcripts, perhaps from a promiscuous association of FMRP with mRNAs from reassociation of FMRP with nontargets after cell lysis and extract preparation or from exogenous FMRP present in the rabbit reticulocyte lysate (RRL) (Beaulieu, 2000) . Moreover, some FMRP nontargets may be bona fide targets of FXR1/2P rather than FMRP, with ribosome stalling also relieved by the kcRNA decoy.
The RRS was not dependent on transcript abundance (R 2 = 0.01), nor the number of associated ribosomes in the steady state (R 2 = 0.07). We observed some correlation between CDS length and RRS among all transcripts (R 2 = 0.41); this was largely due to FMRP targets ( Figure 6E , R 2 = 0.56 for targets; R 2 = 0.17 for nontargets), consistent with FMRP stalling ribosomes across the length of the CDS of its target transcripts. There was a significant difference in the RRS of target and nontarget mRNAs when matched for CDS length ( Figure 6F ). Taken together, these data provide quantitative support for the conclusion that FMRP stalls ribosomes on transcripts to which it is directly bound.
To assess whether the relief of FMRP-dependent ribosome stalling by kcRNA is accompanied by increased protein synthesis, we measured 35 S-methionine incorporation in the IVT EBP assay into two FMRP targets (Camk2a and Lingo1) and one nontarget for which we were able to quantitatively IP protein products. We found a small but significant increase in protein synthesis of both FMRP targets in the absence of functional FMRP, similar to results reported for Camk2a by Osterweil et al. (2010) in slice cultures, with no significant change in either overall protein synthesis or in the synthesis of the nontarget PABP ( Figure 6G and Figure S6 ).
Characterization of the FMRP-Stalled Complex
In some studies, what were initially believed to be translocationblocked polyribosomes were revealed to be ''pseudo-polysomes'' or large mRNP complexes (Thermann and Hentze, 2007) , underscoring the need for caution in making inferences about the components of heavy complexes on sucrose gradients. To determine if the FMRP-stalled complex has the hallmarks of a polyribosome, we first obtained electron-microscopic (EM) images from sucrose gradient fractions after puromycin run-off in the IVT EBP system (fractions 7-8; Figure 3C , middle panel). These fractions harbor complexes containing multiple ribosomes ( Figure 7A ) identified as such by immuno-EM on the same gradient fraction prepared from a transgenic mouse expressing the tagged ribosomal protein EGFP-rpL10a (Heiman et al., 2008 ) ( Figure 7B ). To investigate the association of FMRP with these complexes we expressed EGFP-tagged FMRP in cells, performed a puromycin run-off experiment in vivo, and visualized EGFP-FMRP association with these structures from the puromycin-resistant fractions ( Figure 7C and Figure S7A ). The labeling of these complexes was dependent on FMRP, relative to an overexpressed negative control (EGFP alone; Figure S7B) , demonstrating the physical association of FMRP with stalled polyribosomes in vivo ( Figure 7C ). We then used micrococcal nuclease (MN) as a means of assessing whether the FMRP stalled complex has the features of a typical polyribosome. MN degrades the mRNA exposed between ribosomes, dissociating polyribosomes (but not the ribosomes themselves). Incubation of sucrose-gradient purified polyribosomes with MN, followed by separation of ribosomes from released material on a sucrose cushion, revealed that the majority of FMRP pelleted with the ribosomes (Figures 7D and  7E ). As controls, PABP (bound to mRNA poly(A) tails) was readily released from polyribosomes by MN, whereas rpP0 was MN resistant. Surprisingly, sizing of the puromycin-resistant, MNtreated complex revealed that FMRP remained associated with the large complex up to 1 U/ul MN. At very high MN concentrations (20 U/ul, used to cleave between SRP-associated stacked ribosomes) (Wolin and Walter, 1988) , FMRP is partially released to light fractions, although a substantial fraction ($60%) remains associated with the complex (Figure 7F ). Taken together, these results suggest a close association of FMRP with ribosomes that are stacked or condensed in such a way as to largely prevent MN from cleaving between either FMRP and the ribosomes or between the ribosomes themselves. Consistent with this interpretation, we found that the ultrastructure of the polyribosomal complexes in the MN-treated fractions was indistinguishable from those in untreated fractions ( Figure 7G versus Figure 7A ).
To determine whether FMRP, ribosomes and repressed FMRP target mRNAs are indeed in the same macromolecular complex in the brain, antibodies against rpP0 were used to IP ribosomes from puromycin-and MN-resistant complexes purified on sucrose gradients. FMRP co-IPed with rpP0-containing complexes, as did the ribosomal proteins rpL5 and rpS6 ( Figure 7H ), demonstrating a direct association of FMRP with ribosome-containing complexes, reminiscent of previous findings in cultured cells (Khandjian et al., 1996; Siomi et al., 1996) .
To directly assess FMRP interaction with mRNA in the stalled complexes, we performed FMRP HITS-CLIP on polyribosomes crosslinked after puromycin-run-off in the IVT EBP system. In (C) FMRP binding to target mRNAs (c 2 score) compared with a functional assay (RRS) showed a significant correlation for 39 tested transcripts. Target transcripts (shaded gold) showed high c 2 and RRS scores relative to nontargets (shaded red), with some outliers and two targets deemed to be in a ''grey zone'' (see Table S6 ). Two transcripts, Arc and Gria1 mRNA, are in the ''grey zone.'' Arc falls just below the FDR < 0.1 cutoff for the robust FMRP target list, likely in part because of very low abundance in resting mice (Table S6) This analysis includes every mRNA tested except Arc and Gria1.
(E) RRS is highly correlated with CDS length for FMRP targets (excluding an outlier, Bsn; CDS 11,829 nts).
parallel, CLIP was done on polyribosomes taken from the steady-state (CHX) in the IVT EBP system. In two biological replicate CLIP experiments, we found that FMRP was crosslinked to the same target transcripts ( Figure 7I and Table S7 ) and with the same CDS distribution ( Figure 7J ). Taken together, the most judicious interpretation of these experiments is that FMRP represses translation on polyribosomes in a large complex consisting of target mRNAs and stalled ribosomes.
DISCUSSION
Understanding the pathophysiology of Fragile X syndrome and its extensive overlaps with autism offers the hope of gaining insights into the molecular basis of cognition and behavior. FMRP has been hypothesized to inhibit translation of mRNAs encoding ''plasticity-related proteins'' , and autism can be caused by mutations in proteins that normally limit translation (Kelleher and Bear, 2008) . Here we provide a molecular basis for the overlap between FXS, autism and defects in synaptic plasticity by first showing that many transcripts bound by FMRP encode plasticity-related and other synaptic proteins, and by demonstrating that FMRP represses their translation by stalling ribosomal translocation. These results overlay unbiased, genome-wide target identification with direct biochemical assays of endogenous interactions; although they cannot describe FMRP function on every individual candidate transcript, they provide a statistically robust model for the predominant action of FMRP in translational regulation ( Figure S7C ).
Our data support a model in which FMRP acts to stall ribosomal translocation during elongation as part of a complex containing target mRNAs and ribosomes, analogous to the action of SRP (Wolin and Walter, 1988) . It is increasingly recognized that a large fraction of cellular mRNA may be translated within subcellular domains (Martin and Ephrussi, 2009) , and our data are consistent with FMRP playing a role in controlling such processes. Translational repression by ribosome stalling and stacking may confer several advantages to FMRP in regulating neuronal translation. It may permit translocation to distal sites of protein synthesis (Krichevsky and Kosik, 2001 ) while protecting mRNA from degradation, allow rapid protein synthesis in response to synaptic activation, as seen in response to local application of BDNF (Aakalu et al., 2001) , and immediately slow protein production while recycled ribosomes continue to re-initiate and restore the ''loaded'' state ( Figure 7C ) (Wolin and Walter, 1988) . Although the molecular mechanism by which FMRP stalls ribosomes remains to be determined, it is likely to be dynamic, as it can be acutely reversed by RNA decoys in run-off assays. Such reversibility could be mediated in vivo by FMRP phosphorylation, which has been hypothesized to regulate FMRP's association with apparently stalled polyribosomes in mouse fibroblasts (Ceman et al., 2003) , by FMRP degradation (Hou et al., 2006) , or other means. Agents such as antibiotics that slow ribosomal translocation may help restore the brake on translation lost in FXS, and may be of worthy of clinical consideration.
Although much attention has been paid to the role of FMRP in regulating Hebbian synaptic plasticity through the control of local translation, the bulk of the protein is in the cell body (Christie et al., 2009) . Moreover, FMRP regulates many mRNAs that are probably not localized to the synapse: for example, Bsn and Pclo mRNAs encode proteins that are synthesized in the cell body and transported to the synapse as a complex (Shapira et al., 2003) . These observations suggest that FMRP may play a role in homeostatic synaptic plasticity (Turrigiano, 2008) . In this model, FMRP would act to repress the translation stimulated by neuronal activity to generate a feedback loop limiting neuronal responses to activity at the level of the neuron rather than a specific synapse.
In contrast to HITS-CLIP studies that have identified regulatory sites involved in RNA processing (Licatalosi and Darnell, 2010; Darnell, 2010) , FMRP HITS-CLIP revealed a different and unexpected mode of protein-RNA interaction. We did not identify binding to specific sites suggested by in vitro FMRP RNA selection experiments (G-quadruplex or kissing complex motifs) (Darnell et al., , 2005a Schaeffer et al., 2001) . Moreover, using the RNABob motif-finding program , we found that bioinformatically predicted G-quadruplex motifs are no more abundant in the set of 842 robust FMRP target mRNAs than in an equivalent set of 842 nontargets (controlled for neuronal expression and length; 1112 versus 1068, or 43% versus 39% of targets versus controls, respectively). Indeed, previous studies have shown that the RGG box is not necessary for polyribosome association (Darnell et al., 2005b) and G-quadruplex RNA ligands cannot compete FMRP off polyribosomes (Darnell et al., 2005a) . How FMRP associates with a specific set of mRNAs remains unclear; FMRP may bind to occult RNA motifs, be redistributed on target mRNA, and/or be recruited to targets via protein-protein interactions.
The proteins encoded by FMRP target mRNAs control the balance of activity-dependent translation in synaptic plasticity. They include mGluR5 and the NMDAR subunits and many other components of their macromolecular complexes at the synapse, consistent with the finding that mGluR and NMDAR-dependent synaptic plasticity are altered in FXS mouse models (Harlow et al., 2010; Pilpel et al., 2009) . FMRP also regulates the expression of components of the ERK and mTOR signal transduction pathways that convert receptor activity into translational output, and many downstream pre-and postsynaptic structural, scaffolding, catalytic, receptor, and channel proteins that are likely to be final determinants of changes in synaptic strength.
FMRP target mRNAs are a valuable data set for considering pharmacologic therapy for FXS. mGluR5 inhibitors have shown (F) Six FMRP targets and seven nontargets matched for length (in the 1-2 kbp window) show a significant difference in RRS (RRS Avg(target) = 93.7 +/À 17.6; RRS Avg(nontarget) = 44.8 +/À 8.6; p = 0.040). (G) 35 S-methionine labeled protein synthesized from two FMRP mRNA targets (Camk2a and Lingo1; gold shading) or one nontarget (Pabpc1; red shading) in the IVT EBP system were compared by IP, SDS-PAGE, and Phosphor Imaging, normalizing against irrelevant bands in the IP and a CHX-treated control sample. Error bars represent SEM in all panels, and p values were determined using a two-tailed Student's t test. See also Table S6 and Figure S6 . Figure 3C ). Negative staining with uranyl acetate revealed structures confirmed to be polyribosomes in (B).
(B) Sucrose gradients were prepared from cerebellum of the Purkinje cell-specific Pcp2-promoter driven EGFP-tagged rpL10a BAC transgenic mice (Heiman et al., 2008) , and polyribosome fractions were treated with 6 nM gold-labeled anti-EGFP antibody and processed for EM. Specific staining on clustered structures is indicated (white arrows). Only $1% of polyribosomes showed labeling, consistent with the use of whole cerebellum for analysis, and indicating specificity of the immunogold label.
(C) Immuno-EM images of EGFP-FMRP association with stalled polyribosomal complexes after puromycin run-off in vivo in transfected cells. EGFP-FMRP was detected using 12 nm gold-labeling and antibodies against EGFP. 13.5% of polyribosomes were labeled in the presence of EGFP-FMRP (n = 500) whereas only 0.02% of polyribosomes from EGFP-expressing cells were associated with gold (n = 500).
(D and E) Western blot (WB) analysis (D) and quantitation (E) of the micrococcal nuclease (MN) resistance of FMRP and ribosome co-sedimentation. Polyribosome-containing sucrose gradient fractions of mouse brain extracts were treated with (+) or without (À) 1000 U/ml MN, centrifuged through 15%-20% sucrose, separating proteins as released supernatant (S) or heavy pelleted (P) particles, which were analyzed for the indicated proteins by WB. Error bars represent standard deviation of three independent experiments. (F) Brain extracts were subjected to puromycin run-off, treated with the indicated concentration of MN, purified on 20%-50% sucrose gradients and the indicated proteins analyzed by TCA precipitation and WB; only 25% of fractions 1-3 were precipitated to compensate for their high protein concentrations. Bottom: quantitation of FMRP from samples treated with the indicated concentrations of MN. Signals in lanes 1-3 were multiplied by 4 to compensate for the amount precipitated.
some clinical efficacy, and NMDAR antagonists may also be worthy of clinical consideration. FMRP also targets ERK1 and the mTOR inhibitors Pten, Nf1, and Tsc2, proteins closely linked to autism, supporting the possibility that pharmacologic agents acting on the mTOR and ERK pathways may be clinically relevant for FXS and autism Kelleher and Bear, 2008) . However, FMRP also targets the PI3K-enhancer PIKE (Centg1), and PIKE overexpression in FMRP null mice results in elevated PI3K signaling to the mTOR pathway (Sharma et al., 2010) , indicating the need for care in translating these findings into therapy. The molecular basis for the overlap in symptoms between FXS and autism is poorly understood. The overlap between FMRP targets and the current list of autism susceptibility genes and loci is extensive and sheds light on common pathways, supporting the hypothesis that synaptic dysfunction is critical to the development of autistic features common to both disorders (Kelleher and Bear, 2008) . FMRP and ASD targets fall into several functional categories (Sebat et al., 2007; Pinto et al., 2010) , including synaptic cell adhesion molecules, the NMDAR complex, the mTOR pathway, and regulators of small GTPases.
The FMRP target list also provides a valuable tool for focusing attention on specific gene candidates within multigenic loci for ASD. The three most common syndromic duplications linked to ASD each contain between 13-28 protein-coding genes and harbor at least one FMRP target gene (Table S5) . Moreover, two well-studied candidate genes present in the 17p11.2 and 15q11-13 duplications, Rai1 and Ube3a, harbored FMRP CLIP tags in six of seven and three of seven experiments, respectively; their extremely low expression levels in brain polyribosomes may have precluded their inclusion on the statistically robust FMRP target list. Although the FMRP target set disproportionately overlaps amplified versus deleted ASD-related CNVs, they include genes whose loss results in autism. This is consistent with the gene balance hypothesis, which posits that the same phenotype can arise from under-or overexpression of dosage-sensitive proteins because either disrupts stoichiometry of the same complex (Conrad and Antonarakis, 2007) . Taken together, the relationship between FMRP target transcripts and genes linked to the ASDs, particularly overexpressed genes, provides a new connection between loss of function of FMRP and the development of autistic symptoms in patients.
EXPERIMENTAL PROCEDURES
Mice used as experimental controls were littermates, and experimental results were reproduced in multiple independent experiments as noted throughout.
Male wild-type and Fmr1 tm1Cgr (Fmr1 KO) mouse brain (P11-P25) was used for polyribosome CLIP experiments as described in Extended Experimental Procedures. After high-throughput sequencing, unique CLIP tags were identified and mapped to the mouse mm9 genomic database or RefSeq transcripts. FMRP targets were ranked using a nonparametric method that considered both the total number of tags per gene in each of the seven different CLIP experiments and experimental reproducibility. GO functional category enrichment was analyzed using DAVID 6.7 software. Transcript abundance on polyribosomes was determined from RNA obtained from six littermate pairs of wild-type and Fmr1 tm1Cgr mice (FVB background, P8 males), and data analyzed with Mouse 430 2.0 Gene chips using gcRMA in Bioconductor, as described in Extended Experimental Procedures. FMRP target pathway analysis used the core analysis module of the Ingenuity Pathways Analysis (IPA) knowledge base (http://www.ingenuity.com). The IVT EBP system was generated from postnuclear brain extracts mixed with ATP, amino acids, and RRL, and ribosomes were run-off in the presence of puromycin or hippuristanol or allowed to continue natural elongation without additions. mRNA distribution on sucrose gradients was quantitated by qRT-PCR on an iQ5 Multicolor Real-Time PCR Detection System (BioRad). Experiments gave reproducible results in four of four, two of two, and one biologic replicate with kcRNA decoy, I304N mice, and KO mice, respectively. In sum, these results were consistent in seven of seven experiments using three loss-of-function models.
ACCESSION NUMBERS
Microarray data were deposited in the GEO database with accession number GSE26809.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven figures, and seven tables and can be found with this article online at doi: 10.1016/j.cell.2011.06.013.
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